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J-chain-deficient (Jch2/2) mice were used to study the role of polymeric IgA (pIgA) in primary disease and protective
immunity following genital herpes simplex type 2 (HSV-2) infection. Vaginal IgA in the Jch2/2 mice was composed primarily
of monomeric IgA and was not associated with secretory component (SC). In contrast, vaginal IgA in wild-type (WT) mice was
predominantly polymeric and bound to SC. Following HSV-2 genital infection, the Jch2/2 mice consistently exhibited fewer
vaginal symptoms (P 5 0.010) and mortality (P 5 0.075) than did the WT mice. The variation in disease expression could not
be explained by differences in local viral replication, since titers in vaginal wash fluid were comparable. To assess the effect
of J chain deficiency on protective immunity, WT and Jch2/2 mice were immunized intravaginally with attenuated HSV-2,
challenged intravaginally with wild-type virus 5 weeks later, and evaluated for vaginal infection and neurological disease.
Although the Jch2/2 mice had reduced vaginal HSV-specific IgA and IgG levels following immunization, both WT and Jch2/2
mice were protected from symptoms following wild-type virus challenge. We conclude that pIgA is not required for protective
immunity against genital HSV-2 disease and that J chain deficiency offers some protection against symptoms following
primary HSV-2 genital infection. © 2000 Academic PressINTRODUCTION
Secretory immunoglobulin A (S-IgA) is the predomi-
nant immunoglobulin (Ig) isotype in most mucosal secre-
tions and is presumed to play an important role in pro-
viding protection against pathogens that invade at mu-
cosal surfaces (Mestecky et al., 1999; Murphy, 1999). In
support of this, S-IgA has been shown to prevent viral
attachment to and penetration into epithelial cells as well
as to participate in intraepithelial virus neutralization
(Mazanec et al., 1993; Murphy, 1999). Furthermore, the
presence of specific neutralizing IgA in external secre-
tions has been shown to correlate with resistance to
infection, particularly for diseases of the respiratory and
intestinal tracts (Murphy, 1999). Nonetheless the role of
S-IgA in protecting against infections at the mucosal
surfaces of the female genital tract is less well defined.
A number of investigations have found that IgG is the
most abundant Ig in human genital tract secretions,
whereas IgA predominates at most other mucosal sur-
faces (Mestecky et al., 1999). In addition, most studies
have found that virus-specific antibody is predominantly
IgG rather than IgA in mouse vaginal secretions follow-
1 To whom correspondence and reprints requests should be ad-
ressed. Fax: (773) 702-1196. E-mail: bhendric@peds.bsd.uchicago.
du.
2 Present address: Mount Sinai Hospital and Medical Center, De-
partment of Pediatrics, Annenberg Building, Room 17-271, 1 Gustave L.
Levy Place, New York, NY 10029-6574.
155ing intravaginal immunization with attenuated HSV-2
(McDermott et al., 1990; Milligan et al., 1995; Parr and
Parr, 1997; Parr et al., 1998a). More recently, an IgA-
deficient mouse was used to study the role of IgA in
protective immunity against genital herpes infection (Parr
et al., 1998b). Immunized wild-type (WT) and IgA-deficient
mice were equally protected against intravaginal chal-
lenge with HSV-2, suggesting that IgA is not required for
immune protection (Parr et al., 1998b). However, these
studies have focused primarily on the role of IgA in
protective immunity, whereas little is known about the
function of nonspecific mucosal IgA or secretory compo-
nent in modulating acute disease.
S-IgA is selectively transported into external secre-
tions as polymeric IgA (pIgA) via a receptor-mediated
pathway. J chain is a 15-kDa glycoprotein, which co-
valently associates by disulfide linkages with pIgA prior
to secretion by plasma cells (Koshland, 1985). The pres-
ence of the J chain is necessary for polymeric immuno-
globulin receptor (pIgR)-mediated transport of pIg into
mucosal secretions (Brandtzaeg and Prydz, 1984; Hen-
drickson et al., 1995; Hendrickson et al., 1996). Briefly,
J-chain-containing pIgA binds to epithelial cell surface
pIgR receptors. The pIgA–pIgR complexes then are en-
docytosed into the cell and transported to the luminal
cell surface, where the receptor is proteolytically
cleaved, with a portion of the pIgR known as secretory
component (SC) remaining bound to the pIgA in mucosal
secretions.
We previously reported the generation of J-chain-defi-
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156 HENDRICKSON ET AL.cient (Jch2/2) mice (Hendrickson et al., 1995). Jch2/2 mice
xhibited impaired hepatic IgA transport, with depleted
iliary and fecal IgA levels (Hendrickson et al., 1995). In
ontrast, total IgA levels were not lower in respiratory
ecretions and breast milk, although the IgA was present
n a nonpolymeric form and was not associated with SC
Hendrickson et al., 1996). In this study, we extended
hese observations to the female genital tract and char-
cterized the IgA found in vaginal secretions in Jch2/2
mice throughout the estrous cycle. Although IgA levels
cyclically rose and fell throughout the estrous cycle in
both Jch2/2 and WT mice, Jch2/2 mice had lower trough
IgA levels. In addition, the IgA in vaginal secretions was
present as a monomer and was not associated with SC
in the Jch2/2 mice. To determine the effect of J chain
deficiency on genital HSV-2 infection, we compared the
course of primary genital disease following infection with
wild-type HSV-2 and the development of protective im-
munity following vaccination with attenuated HSV-2 in
Jch2/2 mice and WT mice. Our data suggest that J chain
eficiency was associated with decreased genital dis-
ase following primary infection with HSV-2.
RESULTS
haracterization of Ig in vaginal secretions of Jch2/2
mice compared with WT mice
Samples of vaginal fluid from Jch2/2 and WT mice were
fractionated by SDS–PAGE under nonreducing condi-
tions. IgA was detected by Western blotting with an
anti-mouse a-chain antibody (Fig. 1). As expected, the
IgA detected in WT vaginal fluid was dimeric. However,
the IgA in vaginal fluid from Jch2/2 mice was present
FIG. 1. Vaginal wash samples from WT (1/1) and Jch2/2 (2/2) mice
immunoblotted with anti-IgA and anti-SC antiserum. Vaginal wash flu-
ids collected from WT (n 5 4) and Jch2/2 (n 5 4) mice were electro-
horesed under nonreducing conditions and immunostained with anti-
ouse IgA (left) or anti-SC antiserum (right). A representative blot is
hown. Molecular mass markers in kDa are shown at left.rimarily as a monomer. In addition, in the WT samples,
high molecular weight band consistent with pIgA-as-ociated SC was visible while a band consistent with
pproximately 80 kDa free SC was detected in the Jch2/2
samples (Fig. 1). Thus, while the vaginal IgA in WT mice
was associated with SC, the vaginal IgA in Jch2/2 mice
was not. Of note, the amount of free SC appeared to be
increased in the vaginal secretions of Jch2/2 mice com-
pared with that in WT mice.
To examine the effect of J chain deficiency on the
quantity of vaginal IgA, total IgA levels were measured by
ELISA using vaginal wash (VW) samples pooled from
one estrous cycle (approximately 5 days) from individual
mice to avoid the issue of Ig level variation with different
stages of the estrous cycle (Baker and Plotkin, 1978;
Gallichan and Rosenthal, 1996; Wira et al., 1999). Pooled
W IgA levels were not significantly different between
T and Jch2/2 mice (data not shown). Examination of the
daily vaginal Ig levels over the course of an estrous cycle
revealed that IgA and IgG levels cyclically rose and fell in
both WT and Jch2/2 mice (Fig. 2). However, Jch2/2 mice
were noted to have significantly lower trough IgA levels
(P 5 0.001), whereas trough vaginal IgG levels were
imilar among the WT mice and Jch2/2 mice (Table 1).
eak vaginal fluid IgG levels were not significantly dif-
erent between WT mice and Jch2/2 mice and were lower
han peak IgA levels (Table 1), although the peak vaginal
luid Ig levels were highly variable in the two groups of
ice. In addition, in the WT mice the vaginal IgA and IgG
evels tended to peak at different points during the es-
rous cycle. In contrast, in the Jch2/2 mice the IgA secre-
tion pattern generally paralleled that of IgG (Fig. 2).
Because vaginal Ig levels are hormonally influenced,
we also compared Ig levels following treatment of the
mice with Depo-Provera, a progesterone hormone used
to increase susceptibility to HSV vaginal infection in the
mouse model of genital herpes used below (Baker and
Plotkin, 1978; Overall et al., 1975; Parr et al., 1994). VW
samples were collected from uninfected mice 7 days
following treatment with Depo-Provera and total IgM,
IgA, and IgG levels were measured. Vaginal IgM levels
were similar in WT and Jch2/2 mice (WT 12.4 6 14.7 [n 5
15] vs. Jch2/2 10.1 6 12.1 [n 5 15] ng/ml, P 5 0.64). No
significant differences were noted in the levels of vaginal
IgA or IgG in the Depo-Provera-treated mice, although
the variation within groups was considerable (mean dif-
ference of Jch2/2 2 WT samples, IgA: 612 6 2803 [n 5
6], P 5 0.69 and IgG: 21224 6 2775 [n 5 25], P 5 0.44).
ch2/2 mice exhibited fewer vaginal symptoms
ollowing intravaginal HSV-2 infection
To examine the effect of the variations in IgA secretion
nd structure on genital HSV-2 infection in the Jch2/2
mice, WT and Jch2/2 mice in five separate experiments
were infected intravaginally with HSV-2 following Depo-
Provera treatment. The mice were monitored daily for
vaginal symptoms (erythema, swelling, and ulceration)
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157REDUCED DISEASE IN HSV-INFECTED J-CHAIN-DEFICIENT MICEand scored on a scale of 0 to 4 as outlined under
Materials and Methods. Mice were terminated if they
developed a vaginal symptom score of 4, hind limb pa-
ralysis, or signs of systemic illness. The most notable
finding of these experiments was that Jch2/2 mice exhib-
ited fewer severe vaginal symptoms following HSV-2
genital infection, with 27 of 31 WT mice developing a
FIG. 2. Vaginal IgA and IgG levels versus the estrous cycle in WT a
Jch2/2 (n 5 10) and WT (n 5 10) mice. For each sample, the stage of th
ere determined by ELISA. Ig values graphed are in ng/ml. The stage of
, estrus; m, metaestrus; d, diestrus). Instances where two stages ar
strous stage to the other. Results obtained from two representative W
TABLE 1
Vaginal Ig Levels during the Estrous Cycle in WT and Jch2/2 Micea
Ig WTb (n 5 11) Jch2/2b (n 5 9) P valuec
Trough IgA 465 (38, 1708) 69 (,2, 317) 0.001
Peak IgA 3972 (818, 30153) 3364 (799, 7232) 0.210
Trough IgG 31 (12, 137) 29 (17, 160) 0.569
Peak IgG 1129 (314, 2578) 925 (118, 3586) 0.909
a The highest and lowest IgA and IgG levels measured during one
strous cycle for each individual mouse were included in the analysis.
b Median, minimum, and maximum [Med (Min, Max)] values for each
group are listed. All values are reported in ng/ml.d
c The Wilcoxon rank-sum test was used to compare the Ig levels of
WT and Jch2/2 mice.vaginal symptom score of 2 or greater compared with 18
of 31 Jch2/2 mice (P 5 0.01). In addition, in each of the
ive separate experiments, the Jch2/2 mice had a lower
mortality rate, with 18 of 31 Jch2/2 mice compared with 11
f 31 WT mice surviving at the end of the experiment
P 5 0.075, Table 2). Although also not statistically sig-
ificant, the Jch2/2 mice exhibited a lower rate of hind
imb paralysis in four of the five experiments, with a total
f 9 of 31 Jch2/2 and 16 of 31 WT mice developing hind
limb paralysis (P 5 0.070, Table 2).
VW samples were collected for viral titers on Days 1, 3,
5, 7, and 10 postinfection in three of the experiments and
only on Day 3 postinfection in two of the experiments.
Vaginal fluid viral titers following infection typically were
undetectable on Day 1, peaked on Day 3, and had de-
creased, often to undetectable levels, by Day 7. Among
the mice included in the five experiments, no difference
was noted in the proportion of Jch2/2 and WT mice with
detectable virus in VW collected on Day 3 following
HSV-2 infection (WT 0.75 6 0.12 [n 5 31] vs. Jch2/2 0.72 6
/2 mice. VW samples were collected on sequential days from female
us cycle was assessed by vaginal smear and total IgA and IgG levels
trous cycle corresponding to the Ig level graphed is listed (p, proestrus;
indicate vaginal smears that appeared to be transitioning from one
e (top) and two representative Jch2/2 mice (bottom) are shown.nd Jch2
e estro
the es0.29 [n 5 31], P 5 0.84) or in the number of mice with
etectable virus on Day 5 or Day 7 (Fig. 3). In addition, no
1
c
V
g
h
(
P
i
i
m
t
T
o
w
i
f
s
t
m
V
s
e
l
f
i
s
t
e
e
l
W
J
w
w
s
158 HENDRICKSON ET AL.significant differences were noted in the Day 3 vaginal
fluid viral titers between Jch2/2 and WT mice (WT 3.44 6
0.74 vs. Jch2/2 3.37 6 0.85 mean log10 plaque-forming
units (PFU)/ml 6 SD) (Fig. 3).
HSV-specific IgA and IgG were undetectable in vaginal
secretions by ELISA prior to death in mice infected in-
travaginally with wild-type HSV-2. Thus to examine the
effect of J chain deficiency on the levels of vaginal HSV-
specific Ig, Jch2/2 mice and WT mice were infected with
04 PFU of HSV-2(333/TK2), an attenuated strain that
auses little or no disease in immunocompetent mice.
aginal HSV-specific Ig levels were compared in the two
roups of mice 21 days following infection. Jch2/2 mice
TABLE 2
Comparison of Outcomes in WT and Jch2/2 Mice Following HSV-2
Genital Infectiona
% of Mice WT (n 5 31) Jch2/2 (n 5 31) P valueb
Vaginal score . 2 87% 58% 0.010
HLP 52% 29% 0.070
Survival 35% 58% 0.075
a The data presented are a summary of five separate experiments.
alues listed are the percentage of mice exhibiting a vaginal symptom
core . 2, HLP (hind limb paralysis), and surviving at the end of the
xperiment. Mice were terminated if stage 4 vaginal disease, neuro-
ogic symptoms, or systemic signs of illness were observed. Mice were
ollowed postinfection for 14 days in experiments 1–4 and for 10 days
n experiment 5. Jch2/2 mice had lower vaginal symptom scores and
urvival in five of the five experiments and lower rates of HLP in four of
he five experiments.
b P values were based on Pearson’s chi-square statistic test of the
null hypothesis that the distribution of vaginal score and rates of HLP
and survival were the same in the WT and Jch2/2 mouse groups.
FIG. 3. Percentage of mice with HSV-2 cultured from vaginal washes
collected on Days 1, 3, 5, and 7 postinfection following intravaginal
HSV-2 infection in WT and Jch2/2 mice. Vaginal washes were collected
by pipetting 30 ml of PBS in and out of the vagina five to eight times and
viral titers determined by plaque assay on Vero cell monolayers. Values
graphed represent the sum of three separate experiments (n 5 18 forach group) except for postinfection Day 3, which is the sum of all five
xperiments (n 5 31 for each group).ad lower HSV-specific IgA (P 5 0.004) and IgG levels
P 5 0.016) than WT mice (Table 3).
rotection from wild-type virus challenge following
mmunization with HSV-2(333/TK2)
Immunocompetent mice previously immunized with
HSV-2(333/TK2) are protected from symptoms following
ntravaginal infection with wild-type HSV-2, although the
ice often have replicating virus detectable in the genital
ract transiently (Parr et al., 1998b; Parr and Parr, 1998).
o assess whether the reduced HSV-specific Ig levels
bserved in the immunized Jch2/2 mice were associated
ith a reduction in protective immunity, the mice were
nfected intravaginally 5 weeks post-HSV-2(333/TK2) in-
ection with 104 PFU of HSV-2(333) and monitored for
ymptoms of illness for 14 days. Both WT mice and Jch2/2
mice were protected from symptoms following wild-type
HSV-2 challenge (Table 4). No significant differences
were noted in the peak vaginal fluid viral titers in the
immunized WT and Jch2/2 mouse groups following wild-
ype virus infection (data not shown).
DISCUSSION
This study demonstrates that mice lacking J chain had
onomeric rather than pIgA in vaginal secretions and
TABLE 3
Vaginal HSV-Specific Ig Levels in WT and Jch2/2 Mice
Vaginal Ig WTa (n 5 6) Jch2/2a (n 5 6) P valueb
HSV-specific IgA 0.27 (0.11, 1.32) 0.04 (0.02, 0.08) 0.004
HSV-specific IgG 16.23 (2.61, .25) 2.73 (,0.10, 4.45) 0.016
a Median, minimum, and maximum [Median (Min, Max)] values are
isted.
b The Wilcoxon rank-sum test was used to compare the Ig levels of
WT and Jch2/2 mice.
TABLE 4
Survival Following Wild-Type Virus Challenge in Immune and
Nonimmune WT and Jch2/2 Micea
Mice Immunity Vaginal score . 2 Mice survivingb
WT Immune 0/3 3/3
Jch2/2 Immune 0/3 3/3
T Nonimmune 2/2 0/2
ch2/2 Nonimmune 2/2 0/2
a Mice previously infected with HSV(333/TK2) (immune) or mice
hich were not previously infected with HSV(333/TK2) (nonimmune)
ere challenged intravaginally with wild-type HSV-2. Data are repre-
entative of two separate experiments.
b Mice were terminated if stage 4 vaginal disease, neurologic symp-toms, or systemic signs of illness were observed. Mice were followed
for 14 days post-HSV(333) infection.
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159REDUCED DISEASE IN HSV-INFECTED J-CHAIN-DEFICIENT MICEthat the secreted vaginal IgA was not associated with
SC. Despite these alterations in IgA secretion, the de-
gree of vaginal swelling, erythema, and ulceration fol-
lowing primary HSV-2 genital infection was significantly
less in the Jch2/2 mice. Moreover, the incidence of hind
limb paralysis was lower in the Jch2/2 mice in four of the
ive experiments. Although the rate of viral infection and
iral clearance in the Jch2/2 mice appeared to be similar
o that of WT mice, vaginal fluid viral titers may not
ecessarily reflect viral replication throughout the genital
ract. Thus differences in HSV-2 replication among the
ch2/2 mice versus WT mice may have been missed. Our
data, however, would suggest that variations in the im-
mune response to genital HSV-2 infection between the
Jch2/2 and WT mice are a likely explanation for the
observed differences in vaginal symptom severity.
Previous studies of genital herpes infection in mice
predominantly have focused on defining the components
of the immune system involved in mediating viral clear-
ance and the development of protective immunity from
subsequent viral challenge as a model for vaccine de-
velopment. HSV-specific mucosal IgA and IgG antibod-
ies, T-cell responses, and interferon-g all have been
postulated to play a role (Parr and Parr, 1997, 1998;
Milligan and Bernstein, 1997; Milligan et al., 1998; and
Kuklin et al., 1998). However, our study suggests that the
immune response to HSV-2 genital infection not only is
important for viral clearance and protection from subse-
quent virus challenge, but also may mediate some of the
associated clinical signs or symptoms.
There are several possibilities that could account for
an altered mucosal immune response in the HSV-2-
infected Jch2/2 mice. For example, vaginal fluid from WT
mice contained predominantly pIgA covalently linked to
SC, while Jch2/2 mice had predominantly monomeric IgA
nd free SC in their vaginal secretions. The predomi-
ance of monomeric rather than pIgA in the vaginal fluid
f the Jch2/2 mice may play a role in the diminished
nflammatory response following genital herpes infec-
ion. In support of this notion, some studies have sug-
ested that effects on the immune response by pIgA may
e different from those of monomeric IgA. For example,
n immobilized preparation of pIgA, but not monomeric
gA, induced histamine release from interleukin-3-primed
uman basophils in vitro (Iikura et al., 1998). Secretory
IgA also has been reported to mediate eosinophil stim-
lation (Abu-Ghazaleh et al., 1989; Motegi and Kita,
998). Potentially monomeric IgA and pIgA may have
ifferent effects on Fc a-receptor signaling and cytokine
release by macrophages and neutrophils. Antibody-de-
pendent cellular cytotoxicity (ADCC) may be an important
component of the anti-HSV defense (Kohl, 1991). Studies
have noted varying abilities of different Ig types to me-
diate ADCC (Huls et al., 1999, Ishizaka et al., 1995). Thus,
another possibility is that the alterations in genital tract
m
mIg in the Jch2/2 mice could result in less efficient ADCC
nd consequently less mucosal damage.
Moreover, differences in the concentration of free SC
ight also contribute to differences in the inflammatory
esponse to infection. The amount of free SC appeared to
e elevated in the vaginal secretions in Jch2/2 mice
ompared with those of WT mice. Previous Western blot
nalyses of breast milk of WT and Jch2/2 mice demon-
trated a similar result (Hendrickson et al., 1996). These
ata would suggest that trafficking of the pIgR from the
asal to apical membrane of epithelial cells and release
f SC into the secretions of the reproductive tract occur
n the absence of pIgA transport. Of interest, Johansen et
l. (1999) recently have reported a deterioration of the
pithelial barrier in pIgR/SC-deficient mice, resulting in
levated levels of albumin in saliva and feces. Conceiv-
bly, free SC may have some anti-inflammatory effect
hat contributes to the decreased vaginal symptoms fol-
owing HSV-2 intravaginal infection in Jch2/2 mice.
We also compared the HSV-specific mucosal IgA and
gG responses following infection with attenuated virus
nd found reduced levels of HSV-specific antibodies 3
eeks postinfection in the Jch2/2 mice. Nonetheless,
oth Jch2/2 mice and WT mice were equally protected
from symptoms following subsequent challenge with
wild-type HSV-2. Since J chain is not known to play a role
in IgG secretion, the finding of lower vaginal HSV-spe-
cific IgG levels in the Jch2/2 mice was surprising and
suggests an altered cytokine response to HSV infection
in the Jch2/2 mice. This reduction in mucosal HSV-spe-
ific IgG levels, however, was not associated with any
ncreased susceptibility to disease. This finding is con-
istent with that of Kuklin et al. (1998), who demonstrated
hat the failure to generate anti-HSV antibody in mMT
ice, which lack mature B cells, did not impair the ability
f the immunized mice to resist intravaginal infection by
ild-type virus. In addition, Parr et al. (1998b) have found
hat IgA knockout mice immunized with attenuated virus
ere completely protected following wild-type HSV-2
hallenge. Thus genital mucosal antibody levels do not
ecessarily correlate with protective immunity against
ntravaginal challenge with HSV-2. These results differ
rom those obtained for a number of respiratory and
astrointestinal tract viral pathogens and may reflect
ifferences in local immunity at these sites (Murphy,
999).
Another finding of this study was that vaginal IgA
evels were greater than IgG levels in the nonimmune
ice, which differs from the findings of most human
tudies (Mestecky et al., 1999). Of note, in our study the
rocedure used to extract Ig from vaginal mucus was
imilar to that described by Parr et al. (1998a). In agree-
ent with our observations, Parr et al. (1998a) reported
hat vaginal S-IgA:IgG ratios were 6.7:1 in nonimmune
ice. It is unclear whether the variation in human and
ouse vaginal secretions in this regard is the result of
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160 HENDRICKSON ET AL.differences in the methods used to measure vaginal Ig
levels or a true species difference.
In addition, we found that vaginal IgA levels varied
during the estrous cycle in Jch2/2 mice, despite the fact
that J chain-deficient IgA was not transported by the
pIgR. The pIgR is thought to play a major role in the
transport of pIgA into vaginal secretions (Parr and Parr,
1999; Wira et al., 1999). IgA levels in vaginal secretions
vary during the estrous cycle and this observation has
been attributed, at least in part, to cyclic alterations in the
level of pIgR expression in the reproductive tract (Wira et
al., 1999). Unlike WT mice, the peak and trough levels of
IgA paralleled those of IgG in the Jch2/2 mice, which may
suggest a similar mechanism of transport for IgA and IgG
into vaginal secretions in the Jch2/2 mice. Vaginal HSV-
pecific IgG levels in immunized mice have been re-
orted to be higher in diestrus than in estrus (Baker and
lotkin, 1978). Transudation of IgG through the vaginal
pithelium likely occurs more readily during diestrus
ecause the epithelial layers of the vagina are thinnest at
his point and proteins can penetrate more readily (Bron-
on et al., 1968; Gallichan and Rosenthal, 1996). Since
he IgA in Jch2/2 mice is primarily monomeric rather than
polymeric, transudation of IgA into the vaginal lumen
during diestrus likely occurs to a greater extent than in
WT mice. In contrast, during estrus when the vaginal
epithelium is thickest, the secretion of IgA into the vagina
may be highly dependent on the pIgR transport pathway.
Consequently, our finding that trough vaginal IgA levels
were depressed in the Jch2/2 mice likely reflects a lack of
IgR-mediated transport of J chain-deficient IgA.
In summary, further investigation is necessary to elu-
idate the factors which contribute to the decreased
ocal and neurological symptoms following HSV-2 genital
nfection in Jch2/2 mice. Our study, however, suggests
that J chain deficiency is associated with a dampened
inflammatory response to HSV-2 in the vagina.
MATERIALS AND METHODS
Mice
The Jch2/2 mice were generated as previously de-
scribed (Hendrickson et al., 1995) and bred 10 to 12
generations into the Balb/c (Taconic Laboratories) back-
ground. Age-matched WT Balb/c female mice (Taconic
Laboratories) were used as controls. Mice were housed
in microisolator cages within a barrier facility. This work
was approved by the University of Chicago Animal Care
and Use Committee.
Virus strains
The wild-type strain HSV-2(333) and the bromode-
oxyuridine-resistant mutant of strain 333, which fails to
induce detectable thymidine kinase activity, HSV-2(333/
TK2), were a generous gift of L. Stanberry, Children’s
w
mospital Medical Center, Cincinnati, Ohio (Stanberry et
l., 1985).
aginal washes for Ig determinations
Vaginal washes were collected from the mice by pi-
etting 50 ml of sterile PBS or normal saline in and out of
he vagina five to eight times twice and then mixed with
protease inhibitor cocktail (10 mM leupeptin, 1 mg/ml
protinin, 3.25 mM bestatin, 0.2 mM 4-[2-aminoethyl]-
benzenesulfonyl fluoride; Sigma Chemical Co., St. Louis,
MO). For mice undergoing estrous staging, VW samples
were collected at the same time each day on sequential
days. A 10-ml aliquot from each VW sample was exam-
ned by light microscopy for estrous staging (proestrus/
strus/metaestrus/diestrus) by assessing cell types (lym-
hocytes, epithelial cells) and morphology (cornified ver-
us noncornified epithelial cells). The VW then was
entrifuged and the pelleted cells/mucus were stored
eparately from the supernatant at 220°C until pro-
essed for the Ig ELISAs.
g ELISAs
The VW samples were processed as described by
arr et al. (1997) to optimize Ig recovery. IgA levels were
easured by ELISA. Briefly, MaxiSorp immunoplates
Nunc, Roskilde, Denmark) were coated with a 1:500
ilution of goat anti-mouse IgA antibody (Cappel Re-
earch Products, Durham, NC) in bicarbonate buffer and
locked with 5% nonfat dry milk in PBS. Serial dilutions of
he samples in blocking buffer then were added to the
lates and total IgA was detected with rabbit anti-mouse
gA antibody peroxidase conjugate (1:1000 dilution)/1
g/ml p-nitrophenyl phosphate (Sigma Chemical Co.).
bsorbency readings at 450 nm were compared against
tandard curves generated with purified mouse IgA stan-
ard (Sigma Chemical Co.). IgM and IgG levels were
easured by ELISA as previously described (Hendrick-
on et al., 1995).
gA and SC detection in vaginal washes
Vaginal secretions were fractionated by nonreducing
DS–PAGE on 4% polyacrylamide gels and Western blot
nalysis for IgA and SC performed as outlined previously
Hendrickson et al., 1996). Protein concentrations of the
W samples were adjusted to equivalent levels using the
io-Rad Protein Assay Reagent protocol (Bio-Rad Labo-
atories, Hercules, CA).
ouse model of HSV-2 genital infection
Seven days following the injection of 4- to 6-week-old
alb/c female mice with Depo-Provera (2 mg/mouse sub-
utaneously; Upjohn Company, Kalamazoo, MI), the mice
ere anesthetized (100 mg/kg Ketamine and 7.5–10
g/kg Xylazine, intraperitoneally), placed on their backs,
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161REDUCED DISEASE IN HSV-INFECTED J-CHAIN-DEFICIENT MICEand inoculated intravaginally with 104 plaque-forming
units of either HSV-2 strain 333 or 333/TK2 in 10 ml of
PBS, pH 7.4, or PBS alone. Following wild-type virus
infection, the mice were examined daily by a blinded
observer and scored as to the incidence and severity of
primary disease for 1–14 days. Vaginal symptoms were
scored on a 0 to 4-point scale: 0, no apparent infection;
1, slight redness of the vagina; 2, moderate redness and
swelling of the vagina and surrounding tissue; 3, severe
redness and swelling of the vagina and surrounding
tissue; 4, genital ulceration with severe redness, swell-
ing, and hair loss of genital and surrounding tissue. In
addition, mice were assessed for signs of systemic ill-
ness (i.e., weight loss, decreased activity, change in
grooming behavior) and neurological disease (primarily
hind limb paralysis). Mice reaching stage 4 vaginal dis-
ease, exhibiting hind limb paralysis, or signs of systemic
illness were terminated. For wild-type virus challenge
following HSV-2(333/TK2) infection, mice were again
treated with 2.5 mg/mouse of Depo-Provera 1 week prior
to intravaginal inoculation with 104 PFU of HSV-2(333).
he mice were challenged with wild-type virus 5 weeks
fter HSV-2(333/TK2) infection.
Vaginal washes were collected on Days 1, 3, 5, 7, and
10 (or for some experiments on Day 3 only) postinfection
by pipetting 30 ml of sterile PBS in and out of the vagina
ive to eight times, inoculated into DMEM with 10% FBS,
nd then stored at 280°C. Viral titers were determined
y plaque assay on Vero cell monolayers (African green
onkey kidney cells; American Type Culture Collection,
ockville MD) as previously described (Herold et al.,
991).
easurement of HSV-specific Ig levels
Vaginal HSV-specific IgA and IgG were measured by
LISA similar to that described by Morrison et al. (1998).
Briefly, Immulon-2 plates (Dynatech) were coated with
either an uninfected or HSV-2 infected Vero cell lysate
diluted in PBS, pH 7.2 (total protein concentration of 4
mg/ml), for 18–24 h at 4°C. The plates were blocked with
% goat serum diluted in PBS–Tween (0.1%) for 1.5 h,
ollowed by the addition of VW samples diluted 1:2 or 1:4
n PBS–Tween for 1–2 h. The plates then were incubated
ith biotinylated anti-mouse IgG or anti-mouse IgA anti-
odies (Caltag Laboratories, Burlingame, CA) diluted
:5000 in PBS–Tween for 1 h, followed by strepavidin-
eroxidase conjugate (S5512, Sigma Chemical Co.) di-
uted 1:500 in PBS–Tween for 0.5 h and then substrate
Sigma Fast o-phenylenediamine dihydrochloride tablets;
igma Chemical Co). All incubations were at room tem-
erature and the plates were washed three times with
BS–Tween, followed by three washes with PBS be-
ween steps. A positive control sample pooled from VW
2amples of multiple HSV-2(333/TK )-infected mice and a
negative control sample pooled from VW samples of
Hmultiple nonimmune mice were included in each assay.
The corrected sample OD450 was calculated by subtract-
ing the sample OD450 [uninfected cell lysate-coated well]
rom the sample OD450 [infected cell lysate-coated well].
For comparisons of HSV-specific IgA levels in WT and
Jch2/2 mice, the corrected OD450 of the samples was
ompared to that of the positive control to yield the
SV-specific IgA units for the sample. HSV-specific IgG
alues in ng/ml were calculated using a standard curve
enerated with a purified monoclonal HSV-2 gB antibody
No. 1105, Goodwin Institute for Cancer Research, Plan-
ation, FL).
tatistical analysis
Vaginal Ig levels first were plotted and examined sep-
rately by experiment and mouse type. To compare the
aginal IgA and IgG levels of Depo-Provera-treated mice,
e calculated the difference between the mean level for
he Jch2/2 mice and that for the WT mice for each exper-
ment. A simple average of these differences was then
omputed, and Student’s t test was used to test the null
ypothesis that the underlying mean difference was
qual to zero. P values for the comparisons of vaginal
ymptom scores, hind limb paralysis, and survival be-
ween the WT and Jch2/2 groups were based on Pear-
son’s x2 statistic. HSV-specific IgA and IgG levels in the
SV-2(333/TK2)-infected mice were compared using a
ilcoxon rank-sum test.
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